Neurologic Disease | Role of intravenous immunoglobulin infusion in treatment [33] | Role of therapeutic plasma exchange in treatment [13] |
---|---|---|
Acute inflammatory demyelinating polyneuropathy (AIDP, Guillain-Barré syndrome) | Definite | First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A) |
Chronic inflammatory demyelinating polyneuropathy (CIDP) | Definite | First line therapy with a strong recommendation and moderate quality evidence. (Category I, Recommendation grade 1B) |
Lambert-Eaton myasthenic syndrome (LEMS) | Probable | Second line therapy with a weak recommendation and low quality or very low quality evidence. (Category II, Recommendation grade 2C) |
IgM anti-myelin associated glycoprotein paraprotein associated peripheral neuropathy | Probable | First line therapy with a strong recommendation and low quality or very low quality evidence. (Category I, Recommendation grade 1C) |
Myasthenia gravis (MG) | Probable | First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A) |
Multiple sclerosis (MS) | Possible | Second line therapy with a strong recommendation and moderate quality evidence. (Category II, Recommendation grade 1B) |
Acute disseminated encephalomyelitis (ADEM) | Possible | Second line therapy with a weak recommendation and moderate quality evidence. (Category II, Recommendation grade 2C) |